COL9A2抗体—艾普蒂 新品

+ +

•  

   

     IHC-P analysis of cartilage tissue by COL9A2 antibody (P16025) IHC-P was performed using sections of the formalin-fixed paraffin-embedded cartilage tissue;Result: Chondrocytes are positively stained at the cytoplasm and nuclei.    

  
  

The COL9A2 antibody targets the alpha-2 chain of type IX collagen, a critical component of the extracellular matrix (ECM). Encoded by the COL9A2 gene, this chain combines with alpha-1 (COL9A1) and alpha-3 (COL9A3) chains to form heterotrimeric type IX collagen molecules. These molecules are structurally associated with type II collagen fibrils in cartilage, contributing to ECM stability, tissue integrity, and chondrocyte-matrix interactions. COL9A2 plays a role in cartilage homeostasis and joint function, with mutations linked to skeletal disorders like multiple epiphyseal dysplasia (MED) and early-onset osteoarthritis.

COL9A2 antibodies are essential tools for studying the expression, localization, and functional roles of this protein in health and disease. In research, they are used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to analyze COL9A2 distribution in tissues, particularly cartilage, and to investigate its involvement in degenerative joint conditions. Commercially available antibodies are typically raised in rabbits or mice using peptide antigens specific to human COL9A2. validated for cross-reactivity in model organisms.

Clinically, COL9A2 antibodies may aid in diagnosing genetic collagenopathies or monitoring cartilage degradation biomarkers. However, challenges include ensuring specificity due to structural similarities among collagen family members. Ongoing studies explore their potential in therapeutic development, such as targeting ECM remodeling pathways in osteoarthritis.